Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.
Revenue (Most Recent Fiscal Year) | $84.82M |
Net Income (Most Recent Fiscal Year) | $-21.43M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 7.89 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.60 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -24.60% |
Net Margin (Trailing 12 Months) | -25.26% |
Return on Equity (Trailing 12 Months) | -20.72% |
Return on Assets (Trailing 12 Months) | -16.28% |
Current Ratio (Most Recent Fiscal Quarter) | 5.52 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.27 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 1.73 |
Book Value per Share (Most Recent Fiscal Quarter) | $2.32 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
Earnings per Share (Most Recent Fiscal Year) | $-0.49 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.49 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 43.78M |
Free Float | 34.37M |
Market Capitalization | $669.35M |
Average Volume (Last 20 Days) | 0.34M |
Beta (Past 60 Months) | 0.74 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 21.50% |
Percentage Held By Institutions (Latest 13F Reports) | 70.85% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |